Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 449.03% | 948.62% | 801.96% | 566.99% | 53.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 449.03% | 948.62% | 801.96% | 566.99% | 53.22% |
| Cost of Revenue | 35.37% | 67.42% | 66.22% | 65.40% | 69.30% |
| Gross Profit | 1,608.80% | 628.19% | 435.25% | 227.78% | -190.35% |
| SG&A Expenses | 86.47% | 118.32% | 163.03% | 196.30% | 178.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.76% | 88.99% | 110.88% | 121.49% | 106.89% |
| Operating Income | 29.97% | 15.78% | -23.58% | -63.33% | -128.77% |
| Income Before Tax | 29.19% | 14.97% | -24.87% | -64.99% | -127.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.19% | 14.97% | -24.87% | -65.00% | -127.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.19% | 14.97% | -24.87% | -65.00% | -127.06% |
| EBIT | 29.97% | 15.78% | -23.58% | -63.33% | -128.77% |
| EBITDA | 30.42% | 16.12% | -23.26% | -62.99% | -128.54% |
| EPS Basic | 42.86% | 33.11% | 0.54% | -31.80% | -93.66% |
| Normalized Basic EPS | 43.87% | 34.39% | 3.53% | -28.20% | -92.20% |
| EPS Diluted | 42.82% | 33.18% | 0.66% | -31.63% | -93.01% |
| Normalized Diluted EPS | 43.87% | 34.39% | 3.53% | -28.20% | -92.20% |
| Average Basic Shares Outstanding | 23.60% | 29.23% | 29.36% | 26.90% | 19.38% |
| Average Diluted Shares Outstanding | 23.60% | 29.23% | 29.36% | 26.90% | 19.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |